Antibiotics profile map of clinical A. baumannii strains isolated from health institutions in Turkey: a database search study and analysis of publications from 2011 to 2022

Abstract

Background Acinetobacter baumannii is recognized as a major threat that causes healthcare-associated infections and causes a huge challenge to the health system worldwide. This research study was designed to detect the types and profiles of antibiotics tested against A. baumannii clinical strains in Turkey to evaluate their effectiveness and reevaluate their usage. Main body of the abstract The study depended on data search strategy using the online electronic database. We carried out a detailed analysis to all original research articles from 2011 to 2022 all conducted in Turkey. The study involved 91 articles and revealed about 40 antibiotics tested from 2006 to 2021 against A. baumannii with a different frequency. The more frequency antibiotics tested by health institutions in Turkey during this period included 15 antibiotics which are (Amikacin, Gentamicin, Imipenem, Meropenem, Cefoperazone–sulbactam, Ceftazidime, Cefepime, Ampicillin/sulbactam, Piperacillin, Piperacillin/tazobactam, Ciprofloxacin, Levofloxacin, Trimethoprim–Sulfamethoxazole, Colistin and Tigecycline). The frequency of resistance rate with percentage of (80–100%) shown by A. baumannii against these antibiotics was as follows (40.96%, 50.64%, 77.77%, 78.31%, 46.15%, 94.11%, 88.23%, 80.85%, 95.46%, 91.93%, 93.42%, 82.85%, 53.57%, 2.66%, 3.70%), respectively. From 2016 to 2021, an increase in resistance rates by A. baumannii against Colistin and Tigecycline was indicated noticeably. The 0% resistance rates during this period against Colistin were reported in a percentage of 16.6%, while the appearance of highly noticeable resistance (from 80 to 100 = 3.70%) against Tigecycline and the continuous elevation of resistance rates against this drug was worrisome. Short conclusion Stability in high resistance rates against some antibiotics for the last 10 years and the increase in resistance rates against effective antibiotics by A. baumannii should undergo for more studies and re-evaluation.

Identification of fungus-growing termite-associated halogenated-PKS maduralactomycin a as a potential inhibitor of MurF protein of multidrug-resistant Acinetobacter baumannii

“…The bacterium has intrinsic resistance to a broad range of antibiotics, and acquired resistance mechanisms, such as enzymes inactivating antibiotics, have emerged. The high resistance rate of A. baumannii to Ceftazidime (94.11%), (Cefepime 88.23%) imipenem (77.77%) (Abed et al, 2023) and high mortality rates (50%-64%) have made it a priority-I pathogen according to the World Health Organization, which placed critical category for the urgent need of new antibiotics (Kieny, 2017).…”

Advances in Nanotechnology for Biofilm Inhibition

“…The K. pneumoniae genome contains multiple clusters of genes for chaperones and adhesin proteins for the assembly of fimbriae ( fim, ecp, mrk, kpa , and kpg gene clusters) . Biofilm formation also contributes to the persistence of A. baumannii in the hospital environment, , increasing the risk of cross-contamination and reinfection. Adhesion proteins help A. baumannii and P. aeruginosa cells attach to surfaces and initiate biofilm formation, which includes fimbriae and type IV pili. − Moreover, studies have shown the role of curli fimbriae genes ( csgA and csgD ) in the biofilm formation of Enterobacter isolates .…”